Stroke prevention in atrial fibrillation: WATCHMAN versus warfarin

Expert Review of Cardiovascular Therapy

Volumn 7, Issue 7, 2009, Pages 727-729

  Holmes Jr , David R ^a   Fountain, Rebecca ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; NITINOL; PLACEBO; WARFARIN; ANTICOAGULANT AGENT;

AGE; ARTIFICIAL EMBOLISM; BLEEDING; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; EDITORIAL; GENETIC VARIABILITY; HEART ASSIST DEVICE; HEART ATRIUM APPENDAGE; HEART ATRIUM FIBRILLATION; HIGH RISK POPULATION; HUMAN; HYPERTENSION; IMPLANTATION; INTERNATIONAL NORMALIZED RATIO; MONOTHERAPY; MORBIDITY; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; RISK FACTOR; STROKE; TRANSIENT ISCHEMIC ATTACK; COMPARATIVE STUDY; PROSTHESES AND ORTHOSES; RANDOMIZED CONTROLLED TRIAL;

ANTICOAGULANTS; ATRIAL FIBRILLATION; HUMANS; PROSTHESES AND IMPLANTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; STROKE; WARFARIN;

EID: 70349319385     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.09.64     Document Type: Editorial

References (28)

1. Miyasaka Y, Barnes MF, Gersh GJ et al. Secular trends of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 114(2), 119-125 (2006).
2. Psaty BM, Manolio TA, Kuller LH et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation 96(7), 2455-2461 (1997).
3. Stewart S, Hart CL, Hole DJ, McMurray JJ. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart 86(5), 516-521 (2001). (Pubitemid 32999861)
4. Ruigomez A, Johansson S, Wallander MA, Rodriguez LA. Incidence of chronic atrial fibrillation in general practice and its treatment pattern. J. Clin. Epidemiol. 55(4), 358-363 (2002). (Pubitemid 34245363)
5. Petty GW, Brown RD Jr, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO. Ischemic stroke subtypes: a population-based study of functional outcome, survival, and recurrence. Stroke 31(5), 1062-1068 (2000).
6. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 22(8), 983-988 (1991).
7. Lin HJ, Wolf PA, Kelly-Hayes M et al. Stroke severity in atrial fibrillation. The Framingham Study. Stroke 27(10), 1760-1764 (1996). (Pubitemid 26332500)
8. Gage BF, Waterman AD, Shannon W, Boechler M, Rich NW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285(22), 2864-2870 (2001). (Pubitemid 32537350)
9. Garcia DA, Hylek E. Reducing the risk for stroke in patients who have atrial fibrillation. Card. Clin. 26(2), 267-275 (2008).
10. Go AS, Hylek E, Browsky LH et al. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann. Int. Med. 131(12), 927-934 (1999). (Pubitemid 30005032)
11. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. The European Atrial Fibrillation Trial Study Group. N. Engl. J. Med. 333(1), 5-10 (1995).
12. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. N. Engl. J. Med. 323(22), 1505-1511 (1990).
13. Cooper NJ, Sutton AJ, Lu G, Khunti K. Mixed comparison of stroke prevention treatments in individuals with nonrheumatic atrial fibrillation. Arch. Intern. Med. 166(122), 1269-1275 (2006). (Pubitemid 43967578)
14. Ezekowitz MD, Bridgers SL, James KE et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N. Engl. J. Med. 327(20), 1406-1412 (1992).
15. Connolly SJ, Laupacis A, Gent M et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J. Am. Coll. Cardiol. 18(2), 349-355 (1991).
16. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1(8631), 175-179 (1989). (Pubitemid 19038801)
17. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann. Intern. Med. 146(12), 857-867 (2007).
18. Go AS, Hylek EM, Chang Y et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA 290(20), 2685-2692 (2003). (Pubitemid 37475596)
19. Kangelaris KN, Bent S, Nussbaum RL, Garcia DA, Tice JA. Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin. J. Gen. Intern. Med. 24(5), 656-664 (2009).
20. White HD, Gruber M, Feyzi J et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch. Intern. Med. 167(3), 239-245 (2007). (Pubitemid 46256540)
21. Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg. 61(2), 755-759 (1996).
22. Alberg H. Atrial fibrillation: a study of atrial thrombus and systemic embolism in a necropsy material. Acta Med Scand. 185, 373-379 (1969).
23. Stoddard MF, Dawkins PR, Price CR, Ammash NM. Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: a transesophageal echocardiographic study. J. Am. Coll. Cardiol. 25(2), 452-459 (1995).
24. Ostermayer SH, Reisman M, Kramer PH et al. Percutaneous left atrial appendage transcatheter occlusion (PLAATO system) to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation: results from the international multi-center feasibility trials. J. Am. Card. Coll. Cardiol. 46(1), 9-14 (2005).
25. Sievert H, Lesh MD, Trepels T et al. Percutaneous left atrial appendage transcatheter occlusion to prevent stroke in high-risk patients with atrial fibrillation: early clinical experience. Circulation 105(16), 1887-1889 (2002).
26. Hanna IR, Kolm P, Martin R, Reisman M, Gray W, Block PC. Left atrial structure and function after percutaneous left atrial appendage transcatheter occlusion (PLAATO): six-month echocardiographic follow-up. J. Am. Coll. Cardiol. 43(10), 1868-1872 (2004).
27. Fountain R, Holmes DR Jr, Hodgson PK, Chandrasekaran K, Van Tassel R, Sick P. Potential applicability and utilization of left atrial appendage occlusion devices in patients with atrial fibrillation. Am. Heart J. 152(4), 720-723 (2006). (Pubitemid 44396890)
28. Sick PB, Schuler G, Hauptmann KE et al. Initial worldwide experience with the WATCHMAN left atrial appendage system for stroke prevention in atrial fibrillation. J. Am. Coll. Cardiol. 49(13), 1490-1495 (2007). (Pubitemid 46505070)